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VIEWPOINT
Doxazosin and Congestive Heart Failure
Franz H. Messerli, MD, FACC
New Orleans, Louisiana
Congestive heart failure (CHF) is the most devastating cardiac sequella of long-standing
hypertension. Recent data from the Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) have shown the risk of CHF to be twice as high with
doxazosin than with chlorthalidone. Although some questions remain regarding the diagnosis
and mortality of CHF in the doxazosin arm and regarding the risk of dying from malignancy
in the diuretic arm of ALLHAT, drugs used to treat hypertension should lower the CHF
risk. Therefore, until ironclad safety data are provided, doxazosin, and probably all
alpha-blockers, should no longer be used as first-line antihypertensive therapy. (J Am Coll
Cardiol 2001;38:1295–6) © 2001 by the American College of Cardiology
On May 24, 2001, the U.S. Food and Drug Administration
held a public meeting to discuss a petition requesting the
agency to notify the medical community and users of
doxazosin of the recent findings of the Antihypertensive and
Lipid Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). The study showed that patients using doxazo-
sin were twice as likely to be hospitalized for congestive
heart failure (CHF) and had a higher risk of suffering from
certain serious cardiac events than patients using chlortha-
lidone (1,2). After several hours of deliberation, the Car-
diovascular Drugs Advisory Committee decided that, in-
deed, this information should be made available to
physicians in the package insert, but refrained from recom-
mending a change in the labeling of indications for doxazo-
sin or other alpha-blockers. Thus, most likely, alpha-
blockers will continue to be used as first-line therapy in
patients with essential hypertension, as was recommended
by the Joint National Committee four years ago (3), long
before the findings of the ALLHAT study were known.
Congestive heart failure is a common outcome of hyper-
tensive heart disease. In the Framingham cohort, more than
90% of patients with CHF had a history of hypertension (4),
and long-standing hypertensive cardiovascular disease in-
variably leads to CHF. The prevention of CHF must,
therefore, be considered as one of the major therapeutic
goals in the treatment of hypertension. Indeed, most major
drug classes (diuretics, angiotensin-converting enzyme
[ACE] inhibitors and calcium antagonists) that the Joint
National Committee recommended for initial therapy of
hypertension have been shown to reduce the risk of CHF
when compared with placebo or active therapy. Before
publication of the first results of the ALLHAT study in
March 2000, however, no such data and no morbidity or
mortality data were available for alpha-blockers, despite the
fact that this class of drugs has been promoted and used for
the treatment of hypertension for more than 20 years.
In the Vascular Heart Failure Trial study, treatment with
another alpha-blocker—prazosin, 5 mg twice a day—also
showed no benefits in patients with CHF when compared
with placebo, whereas cumulative mortality was lowered by
38% with combination therapy of isosorbide dinitrate and
hydralazine (5). The data from the ALLHAT study indi-
cate that the risk of CHF with doxazosin was more than
100% (relative risk 2.04; 95% confidence interval 1.79–2.32)
higher than the risk in patients who were treated with
chlorthalidone (1). Although systolic blood pressure was 2
to 3 mm Hg higher in the doxazosin group than in the
diuretic group (diastolic blood pressure was equal), this
difference is unlikely to explain the excessive incidence of
CHF. The small systolic pressure difference could account,
however, for the 25% increased risk of combined cardiovas-
cular events in the doxazosin arm.
Interestingly enough, all-cause mortality in the chlortha-
lidone arm was very similar to that in the doxazosin arm in
CHF patients in the ALLHAT study. This would indicate
either that patients on doxazosin had a remarkably benign
nonlethal form of CHF or that patients in the diuretic arm
died more commonly from causes other than CHF. Con-
gestive heart failure was a secondary end point and, because
there was no regular end point committee, it was poorly
defined in the ALLHAT study. This raises the question of
whether vasodilatory edema, not an uncommon side effect
of alpha blockade (6), could have been misdiagnosed as
CHF in some patients. Also, before randomization to
doxazosin, many patients most likely were receiving diuret-
ics or ACE inhibitor drug classes that are known to be
beneficial in the management of CHF. The switch to
doxazosin may, therefore, merely have unmasked CHF in
patients with left ventricular dysfunction rather than causing
CHF per se.
A very recent report (7) seems to shed some light on this
puzzle by showing that mortality from CHF was not
unexpectedly low in the doxazosin arm and that, surpris-
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ingly, patients using diuretics died more often from extra-
cardiovascular causes. Specifically, the risk of dying from
malignancy was 50% (14% vs. 9%) higher in patients
using chlorthalidone than in those using doxazosin (7).
Although this difference was not statistically significant, it
seems to lend credence to the observation that long-term
diuretic therapy has been associated with an increased risk
for certain malignancies, such as renal cell carcinoma and
colon cancer (8,9).
In contrast, doxazosin has been shown to suppress human
prostate cancer cell growth by inducing apoptosis among
epithelial cells and could, therefore, lower the risk of
prostate cancer (10). As provocative and plausible as this
explanation may seem, it must be interpreted with great
caution because it is based on the small number of patients
with CHF only. However, the ALLHAT study was pow-
ered to provide a more definite answer to this question, and
malignancy data in the diuretic and the doxazosin arm
should have been made available to the medical community
at the time the doxazosin arm was stopped. This could
throw light on the fascinating hypothesis that antihyperten-
sive drug classes differ not only with regard to prevention of
cardiovascular events but also with regard to morbidity and
mortality from extracardiovascular causes such as malig-
nancy (11).
In numerous drug company-sponsored symposia and
journal supplements, alpha-blockers have been touted as
being more beneficial than other antihypertensive drug
classes because alpha-blockers not only lowered arterial
pressure but also had additional benefits in that they
improved insulin resistance and lipid abnormalities. Physi-
cians, therefore, have been under the impression that these
drugs were particularly efficacious for the prevention of
hypertensive heart disease. Although this may be possible
for coronary heart disease (the rate of which was similar in
the diuretic and doxazosin arm despite lessened blood
pressure control), doxazosin does not seem to prevent the
most common cardiac complications of long-standing hy-
pertension, namely CHF. Recent data from the Framing-
ham Heart Study have shown that the prognosis for survival
after the onset of hypertensive CHF remains bleak (4).
Once CHF was diagnosed, only 24% of men and 31% of
women survived five years. These findings suggest that until
ironclad safety data in patients with CHF are provided,
doxazosin, and probably all alpha-blockers as a class, should
no longer be used as initial therapy in the treatment of
hypertension and that these drugs should be used with
caution, if at all, even as add-on therapy in hypertension or
for symptomatic relief of prostatic hyperplasia in patients at
risk of CHF.
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Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ALLHAT  Antihypertensive and Lipid Lowering
Treatment to Prevent Heart Attack Trial
CHF  congestive heart failure
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